<DOC>
	<DOCNO>NCT02119065</DOCNO>
	<brief_summary>This pilot clinical trial study positron emission tomography ( PET ) /computed tomography ( CT ) find bead Yttrium-90 bead therapy patient primary liver cancer cancer spread liver ( metastatic ) remove surgery . Imaging procedure , PET/CT Yttrium-90 bead therapy , may help see beads present lung compare result pre-therapy imaging .</brief_summary>
	<brief_title>Pilot Study Assess Lung Shunting Yttrium-90 Microspheres Using PET/CT</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate absolute difference post-therapy Yttrium-90 microsphere hepatopulmonary shunt fraction pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction patient unresectable primary hepatic malignancy hepatic metastatic disease . SECONDARY OBJECTIVES : I . To quantify compare pre-therapy Technetium-99m macroaggregated albumin particle size post-therapy Yttrium-90 microsphere size . OUTLINE : Patients receive routine pre-therapy Technetium-99m macroaggregated albumin . Patients undergo routine radioembolization Yttrium-90 microspheres . Within 36 hour radioembolization , patient undergo PET/CT imaging . Available imaging , clinical , interventional surgical follow-up data 2 year completion enrollment study obtain .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients undergo intraarterial hepatic 99mTc MAA evaluation anticipation 90Y microsphere radioembolization Patients unable give consent Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Yttrium-90 Radioembolization</keyword>
	<keyword>hepatic malignancy</keyword>
	<keyword>hepatic metastatic disease</keyword>
</DOC>